


Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: *In vivo* study of SHR8443 in mouse xenograft models. U-87MG, PC-3, A549, BT-474 and BT-474/trastuzumab tumor-bearing mice were orally administered with BEZ235 or SHR8443 daily, or intravenously injected with trastuzumab twice a week. Body weight was determined twice a week.